Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (TNDM) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Tandem Diabetes Care, Inc. (TNDM), featuring income statements, balance sheets, and cash flow data.
Tandem Diabetes Care, Inc. (TNDM) Income Statement & Financial Overview
View the income breakdown for Tandem Diabetes Care, Inc. TNDM across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $234.42M | $282.65M | $363.29M | $221.91M |
| Cost of Revenue | $116.02M | $125.19M | $238.64M | $109.12M |
| Gross Profit | $118.41M | $157.46M | $124.65M | $112.79M |
| Gross Profit Ratio | $0.51 | $0.56 | $0.34 | $0.51 |
| R&D Expenses | $125.43M | $52.20M | $51.11M | $49.33M |
| SG&A Expenses | $113.85M | $105.84M | $99.64M | $94.24M |
| Operating Expenses | $239.28M | $158.04M | $150.75M | $143.57M |
| Total Costs & Expenses | $355.30M | $283.23M | $389.38M | $252.68M |
| Interest Income | $0.00 | $4.51M | $5.34M | $2.82M |
| Interest Expense | $0.00 | $1.86M | $1.86M | $1.79M |
| Depreciation & Amortization | $4.31M | $4.25M | $4.21M | $4.11M |
| EBITDA | -$116.42M | $6.12M | -$16.54M | -$23.84M |
| EBITDA Ratio | -$0.50 | $0.02 | -$0.05 | -$0.11 |
| Operating Income | -$120.88M | -$582000.00 | -$26.09M | -$30.77M |
| Operating Income Ratio | -$0.52 | -$0.002 | -$0.07 | -$0.14 |
| Other Income/Expenses (Net) | -$1.21M | $598000.00 | $3.48M | $1.03M |
| Income Before Tax | -$122.09M | $16000.00 | -$22.61M | -$29.74M |
| Income Before Tax Ratio | -$0.52 | $0.00 | -$0.06 | -$0.13 |
| Income Tax Expense | $8.47M | -$739000.00 | $637000.00 | $1.07M |
| Net Income | -$130.56M | $755000.00 | -$23.25M | -$30.81M |
| Net Income Ratio | -$0.56 | $0.003 | -$0.06 | -$0.14 |
| EPS | -$1.97 | $0.01 | -$0.35 | -$0.47 |
| Diluted EPS | -$1.97 | $0.01 | -$0.35 | -$0.47 |
| Weighted Avg Shares Outstanding | $66.40M | $65.94M | $65.54M | $64.99M |
| Weighted Avg Shares Outstanding (Diluted) | $66.40M | $66.16M | $65.54M | $64.99M |
Financial performance has remained strong, with revenue growing from $221.91M in Q2 2024 to $234.42M in Q1 2025. Gross profit continued to perform well, with margins at 51% in the latest quarter. Operating income reached -$120.88M in Q1 2025, holding a steady -52% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$116.42M. Net income dropped to -$130.56M, keeping EPS at -$1.97. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan